A detailed history of Massachusetts Financial Services CO transactions in Alector, Inc. stock. As of the latest transaction made, Massachusetts Financial Services CO holds 174,718 shares of ALEC stock, worth $711,102. This represents 0.0% of its overall portfolio holdings.

Number of Shares
174,718
Previous 112,920 54.73%
Holding current value
$711,102
Previous $512,000 59.18%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.34 - $6.58 $268,203 - $406,630
61,798 Added 54.73%
174,718 $815,000
Q2 2024

Aug 09, 2024

BUY
$4.19 - $6.23 $15,880 - $23,611
3,790 Added 3.47%
112,920 $512,000
Q1 2024

May 14, 2024

BUY
$5.69 - $8.08 $499,866 - $709,828
87,850 Added 412.83%
109,130 $656,000
Q4 2023

Feb 08, 2024

SELL
$3.77 - $8.39 $2,529 - $5,629
-671 Reduced 3.06%
21,280 $169,000
Q3 2023

Nov 08, 2023

SELL
$5.2 - $8.77 $4,373 - $7,375
-841 Reduced 3.69%
21,951 $142,000
Q2 2023

Aug 09, 2023

SELL
$5.86 - $7.93 $3,146 - $4,258
-537 Reduced 2.3%
22,792 $136,000
Q1 2023

May 10, 2023

SELL
$5.85 - $9.84 $317,467 - $533,997
-54,268 Reduced 69.94%
23,329 $144,000
Q4 2022

Feb 13, 2023

SELL
$6.88 - $9.55 $262,616 - $364,533
-38,171 Reduced 32.97%
77,597 $716,000
Q3 2022

Nov 09, 2022

BUY
$8.19 - $13.2 $676,698 - $1.09 Million
82,625 Added 249.3%
115,768 $1.1 Million
Q2 2022

Aug 09, 2022

SELL
$7.65 - $14.24 $941,860 - $1.75 Million
-123,119 Reduced 78.79%
33,143 $337,000
Q1 2022

May 11, 2022

BUY
$13.02 - $20.78 $1.61 Million - $2.57 Million
123,489 Added 376.8%
156,262 $2.23 Million
Q4 2021

Feb 10, 2022

BUY
$19.35 - $25.54 $634,157 - $837,022
32,773 New
32,773 $677,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $336M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.